PVR and neoplasm: TIGIT competes with the immunoactivator receptor CD226 (DNAM-1) for the same ligands: CD155 (poliovirus receptor, PVR) and CD112 (Nectin-2 or PVRL2), expressed on APCs, T cells and some non-hematopoietic cell types like tumor cells (78).